Empowering the body’s natural defenses against life-threatening cancers.

T cell Antigen Coupler (TAC) Platform

Leveraging a T cell’s own recognition, activation and signaling properties.

Our proprietary TAC technology utilizes a novel mechanism of action (MoA) with the potential to enhance the immune response of millions of patients with difficult-to-treat tumors.

Conquering new frontiers in cell therapy.

Co-opting Natural
T Cell Biology

TAC enables T cells to locate and destroy tumor cells through natural activation and maximal, controlled anti-tumor responses.

Broad Applicability
in Cancers

By enabling T cells to target cancer cells using different antigens, TAC may be applied across a wide range of liquid and solid tumors.

Innovative Capabilities in
T cell Manufacturing

We leverage the most advanced manufacturing technologies for optimum product quality.

Co-opting Natural
T Cell Biology

TAC enables T cells to locate and destroy tumor cells through natural activation and maximal, controlled anti-tumor responses.

Broad Applicability
in Cancers

By enabling T cells to target cancer cells using different antigens, TAC may be applied across a wide range of liquid and solid tumors.

Innovative Capabilities in
T cell Manufacturing

We leverage the most advanced manufacturing technologies for optimum product quality.

Pipeline & Programs

Building a robust pipeline of TAC-T cell therapies.

We are developing multiple TAC-based therapeutic candidates using both autologous and allogeneic manufacturing approaches. All programs leveraging our TAC technology have the potential for broad applicability across cancers with a high unmet need.

Recent News

June 23, 2022

CAR T cells headline HER2 cell therapy pipeline

May 31, 2022

L7 Informatics and Triumvira Immunologics Announce Agreement…

April 10, 2022

Triumvira Immunologics to Present Two Posters Covering Ongoi…

June 23, 2022

CAR T cells headline HER2 cell therapy pipeline

May 31, 2022

L7 Informatics and Triumvira Immunologics Announce Agreement…

April 10, 2022

Triumvira Immunologics to Present Two Posters Covering Ongoi…

Interested in learning more?